Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
|
Quantum Biopharma Ltd. (Name of Issuer) |
Common Stock (Title of Class of Securities) |
74764Y205 (CUSIP Number) |
Malone Wealth Ventures 9201 W State St. Ste 126, Boise, ID, 83714 2089854526 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
06/12/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 74764Y205 |
| 1 |
Name of reporting person
Malone Wealth Ventures LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
 (a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
CALIFORNIA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
496,062.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
14.6 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IA |
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock |
| (b) | Name of Issuer:
Quantum Biopharma Ltd. |
| (c) | Address of Issuer's Principal Executive Offices:
FIRST CANADIAN PLACE, 100 KING STREET WEST, SUITE 4000, TORONTO,
ONTARIO, CANADA
, M5X 1A4. |
| Item 2. | Identity and Background |
| (a) | Wealth Ventures LLC |
| (b) | 9201 W State St. Ste. 126. Boise, ID 83714 |
| (c) | Investment Adviser; Malone Wealth Ventures LLC, 9201 W State St. Ste. 126. Boise, ID 83714 |
| (d) | None |
| (e) | None |
| (f) | Unites States |
| Item 3. | Source and Amount of Funds or Other Consideration |
The securities were acquired in open market transactions using funds from client investment accounts managed by Malone Wealth Ventures LLC under discretionary authority. No borrowed funds were used to acquire the securities. | |
| Item 4. | Purpose of Transaction |
The securities were acquired for investment purposes in the ordinary course of business. Malone Wealth Ventures LLC does not have any plans or proposals which would relate to or result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. | |
| Item 5. | Interest in Securities of the Issuer |
| (a) | 496,062. 14.6 |
| (b) | 496,062 |
| (c) | On June 11, 2025, Malone Wealth Ventures LLC, acting on behalf of client accounts under discretionary management, purchased an aggregate of 38,214 shares of Common Stock of Quantum Biopharma Inc. in a series of open market transactions. The purchases were effected on public markets at prices ranging from approximately 6.50 to $19.05 per share. All shares were purchased using client funds and were acquired in the ordinary course of investment management. |
| (d) | Clients of Malone Wealth Ventures LLC may be entitled to receive or direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. To the best knowledge of the reporting person, no individual client has such interest relating to more than five percent of the class of securities. |
| (e) | Not applicable. |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
Kevin Malone, Chief Executive Officer of Malone Wealth Ventures LLC, currently serves as an Advisor to the Board of Directors of Quantum Biopharma Inc. In connection with this role, Mr. Malone entered into a written consulting agreement dated April 15, 2025, pursuant to which he received 30,000 shares of Common Stock and is entitled to additional share compensation based on specified market capitalization and shelf-offering milestones. Malone Wealth Ventures LLC does not, and will not, act on material nonpublic information obtained through this advisory role. All client trading is conducted in accordance with applicable securities laws. Except as described herein, the reporting person does not have any other contracts, arrangements, understandings, or relationships with respect to the securities of the issuer, including but not limited to transfer or voting of any of the securities, derivative instruments, or proxy arrangements. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|